Will provide pre-clinical and specialist services from four facilities
The newly established group created through the merger of CIT and LAB Research will be called CiToxLAB and provide a comprehensive range of pre-clinical and specialist services from four facilities in France, Canada, Denmark and Hungary.
With combined revenues in excess of US$100m, and more than 800 employees, the new group claims to be a major global player in the preclinical outsourcing arena.
’We are confident that this merger will make CiToxLAB an even more attractive partner for our traditional pharmaceutical and biotech clients,’ said group president Jean-Francois Le Bigot. ‘We can offer all the benefits of local, smart-sized facilities, backed up by global resources.’
Le Bigot added that CiToxLAB’s size and capacities also allow the company to offer turnkey solutions.
‘From a single point of entry into the group, we can offer Big Pharma global packages in preclinical testing, seamlessly coordinated by our project managers,’ he said.
Through associate companies and partners such as Atlanbio (St-Nazaire, France), Stemina (Madison, USA) and Biomodels (Boston, USA), CiToxLAB can offer access to further services such as clinical bioanalysis, embryonic stem cell biomarker discovery and customised preclinical efficacy models.